Related Experiment Video
Updated: Mar 19, 2026
Robust Generation of Hepatocyte-like Cells from Human Embryonic Stem Cell Populations
Published on: October 26, 2011
Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening
María José Gómez-Lechón1,2, Laia Tolosa3
1Unidad de Hepatología Experimental, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe de Valencia, Torre A, 6ª Planta, Avenida Fernando Abril Martorell 106, 46026, Valencia, Spain.
Abstract:
Drug-induced liver injury (DILI) is a frequent cause of failure in both clinical and post-approval stages of drug development, and poses a key challenge to the pharmaceutical industry. Current animal models offer poor prediction of human DILI. Although several human cell-based models have been proposed for the detection of human DILI, human primary hepatocytes remain the gold standard for preclinical toxicological screening. However, their use is hindered by their limited availability, variability and phenotypic instability. In contrast, pluripotent stem cells, which include embryonic and induced pluripotent stem cells (iPSCs), proliferate extensively in vitro and can be differentiated into hepatocytes by the addition of soluble factors. This provides a stable source of hepatocytes for multiple applications, including early preclinical hepatotoxicity screening. In addition, iPSCs also have the potential to establish genotype-specific cells from different individuals, which would increase the predictivity of toxicity assays allowing more successful clinical trials. Therefore, the generation of human hepatocyte-like cells derived from pluripotent stem cells seems to be promising for overcoming limitations of hepatocyte preparations, and it is expected to have a substantial repercussion in preclinical hepatotoxicity risk assessment in early drug development stages.
Insights
Induced pluripotent stem cells (iPSCs) offer a stable, renewable source for generating hepatocyte-like cells. This advance promises improved preclinical drug-induced liver injury (DILI) screening, enhancing drug development success rates.
Area of Science:
- Hepatology
- Toxicology
- Stem Cell Biology
Background:
- Drug-induced liver injury (DILI) is a major hurdle in drug development, with current animal models showing poor predictive accuracy for human responses.
- Human primary hepatocytes, the gold standard for DILI screening, face limitations due to scarcity, variability, and instability.
- Existing cell-based models for DILI detection have not fully overcome these challenges.
Purpose of the Study:
- To explore the potential of pluripotent stem cells, specifically induced pluripotent stem cells (iPSCs), for generating a stable and scalable source of hepatocyte-like cells.
- To evaluate the utility of iPSC-derived hepatocytes for preclinical hepatotoxicity screening in early drug development.
- To investigate how genotype-specific iPSC lines can enhance the predictivity of toxicity assays.
Main Methods:
- Differentiation of pluripotent stem cells (including iPSCs) into hepatocyte-like cells using soluble factors in vitro.
- Utilizing these iPSC-derived hepatocytes for early preclinical hepatotoxicity screening.
- Establishing genotype-specific iPSC lines from diverse individuals.
Main Results:
- Pluripotent stem cells, particularly iPSCs, can be extensively proliferated in vitro and differentiated into functional hepatocytes.
- This differentiation process provides a stable and renewable source of hepatocytes, overcoming the limitations of primary cells.
- The potential for creating genotype-specific iPSC-derived hepatocytes offers a pathway to more predictive toxicity assays.
Conclusions:
- Human hepatocyte-like cells derived from pluripotent stem cells represent a promising solution for overcoming the limitations of primary hepatocyte preparations.
- This approach is expected to significantly improve preclinical hepatotoxicity risk assessment in the early stages of drug development.
- The use of iPSC-derived hepatocytes could lead to more successful clinical trials by enhancing the accuracy of toxicity predictions.
